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http://dx
1284Background:Thrombosis occurs in up to 30% of patients with various forms of congenital single ventricle after
the Fontan procedure. We investigated hemostatic abnormalities in adult Fontan patients.
Methods: Forty-eight Fontan patients between ages 18 and 40 years, including 10 (21%) patients with previous
thromboembolism 5 to 15 years after surgery, and 35 control subjects matched for age and sex were studied.
Coagulation factors and inhibitors, together with markers of fibrinolysis, platelets, and endothelial activation,
were determined in peripheral venous blood plasma.
Results: Compared with control subjects, Fontan patients showed lower, although mostly within normal ranges,
values of all coagulation factors, as well as reduced free protein S, in association with higher antithrombin and
free tissue factor pathway inhibitor levels. Thrombin generation, reflected by prothrombin fragment 1.2, and
platelet activation markers were increased in Fontan patients. The plasma clot lysis time was prolonged in
Fontan patients, which was associated with an increased activity of thrombin-activatable fibrinolysis inhibitor.
Fontan patients with previous thromboembolism had lower oxygen saturation, coagulation factors V and VIII,
and free protein S, and increased vonWillebrand factor, soluble CD40 ligand, and P-selectin. Other laboratory or
clinical parameters were not associated with prior thrombotic episodes.
Conclusions: Adult Fontan patients are characterized by enhanced platelet activation and endothelial injury,
heightened thrombin formation, and impaired fibrinolysis. Patients showed reduced free protein S levels,
increased platelet activation, and endothelial damage after thromboembolic events observed late after Fontan
surgery. Our findings indicate novel prothrombotic mechanisms in adult Fontan patients, which might help to
optimize thromboprophylaxis. (J Thorac Cardiovasc Surg 2014;147:1284-90)Fontan surgery has become the treatment of choice in
patients with single-ventricle physiology. The purpose of
this procedure is to normalize volume load of the ventricle
and separate the pulmonary and systemic circulation to
achieve normal or near-normal levels of blood oxygen.
Several modifications of the Fontan surgery can provide
excellent palliation for patients with various forms of single
ventricles.1 Long-term follow-up evaluation of Fontan
patients showed an 85% survival rate.2,3 The longer the
time since the procedure, the more frequently remote
complications occur. In addition, thrombosis occurs in 8%
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systemic ventricle, or ligated pulmonary artery.
Asymptomatic pulmonary emboli have been reported in
17% of Fontan patients.6 Thrombosis risk factors
reported in Fontan patients involve arrhythmias, slow
venous flow, increased central venous pressure, cyanosis,
ventricular dysfunction, liver injury, and effusion protein-
losing enteropathy.5,7 A high prevalence of chronic venous
insufficiency in adult Fontanpatients alsohas been reported.8
Studies on alterations of blood coagulation after Fontan
surgery conducted in children showed lower plasma levels
of coagulation factor (F) V, VII, and VIII, along with low
protein C, free protein S, and plasminogen levels.5,9-12
Mechanisms underlying thromboembolism in Fontan
patients are unclear. Odegard et al13 showed that an increase
in FVIII after Fontan surgery and a decrease in protein C
levels were associated with a high risk of thrombosis in 37
patients (age, 49 mo) with hypoplastic left heart
syndrome from stage I through Fontan completion. In
Fontan patients ages 7 to 26 years, increased vonWillebrand
factor (vWF) levels have been observed, suggesting endo-
thelial damage.14 It has been reported that efficiency of fibri-
nolysis is preserved in those patients based on normal plasma
tissue-type plasminogen activator andplasminogen activator
inhibitor-1 (PAI-1).We performed a comprehensive analysisgery c April 2014
Abbreviations and Acronyms
CLT ¼ clot lysis time
ELISA ¼ enzyme-linked immunosorbent assay
F ¼ factor
PAI-1 ¼ plasminogen activator inhibitor-1
Sao2 ¼ oxygen saturation
TAFI ¼ thrombin activatable fibrinolysis inhibitor
TFPI ¼ tissue factor pathway inhibitor
vWF ¼ von Willebrand factor
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adult Fontan patients.We investigated hemostatic abnormal-
ities observed in adult Fontan patients to identify those
associated with thromboembolism after the procedure.C
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Study Participants
Forty-eight white Fontan patients (26 men, 22 women) ages 18 to 40
years and 35 apparently healthy control subjects matched for age and sex
were included in the study. They were recruited between January 2011
and December 2011. The exclusion criteria were as follows: any acute
illness, cancer, renal insufficiency (creatinine level>120 mmol/L), diabetes
mellitus, an acute vascular event, alcohol abuse, or pregnancy.
Echocardiography was performed in all the patients and single-ventricle
systolic function was assessed.10 Oxygen saturation (SaO2) was measured
by pulse oximetry.
The diagnosis of deep vein thrombosis was established by a positive
finding of color duplex sonography. The diagnosis of pulmonary embolism
was based on the presence of typical symptoms and positive results of
high-resolution spiral computed tomography. Stroke was diagnosed based
on theWorld Health Organization criteria. In Fontan patients with previous
thromboembolic events, thrombophilia screening including FV Leiden,
20210A prothrombin mutation, deficiencies in natural anticoagulants and
antiphospholipid antibodies was performed.
The University Ethical Committee approved the study and patients
provided written informed consent.
Laboratory Investigations
Fasting blood samples were collected into 0.1 volume of 3.2%
trisodium citrate from the antecubital vein with minimal stasis on the
same day that clinical data were recorded. In anticoagulated patients, blood
was drawn at least 5 days after anticoagulation withdrawal. Citrated blood
samples were centrifuged at 3000 g for 20 minutes and stored in aliquots at
–80C until further use. Red blood cell count, white blood cell count,
platelet count, hematocrit level, total protein level, alanine aminotrans-
ferase level, creatinine level, C-reactive protein level, and international
normalized ratio were assayed by routine laboratory techniques.
Coagulation Proteins
Fibrinogen was determined using the thrombin clotting time method.
Prothrombin and coagulation factors (F)V, FVII, FVIII, FIX, and FX
were measured by 1-stage clotting assays using factor-deficient plasmas
(Siemens, Marburg, Germany). Antithrombin activity was measured using
Berichrom (Siemens). Free (ie, active) tissue factor pathway inhibitor (free
TFPI) was determined by an enzyme-linked immunosorbent assay
(ELISA) (Diagnostica Stago, Asnieres, France). Protein C activity was
measured using a chromogenic substrate assay (Siemens). Free protein S
was determined using a latex ligand immunoassay (InstrumentationThe Journal of Thoracic and CarLaboratory, Milan, Italy). The immunoenzymatic assay was used to deter-
mine plasma prothrombin fragments 1.2 (F1.2; Siemens).
Fibrinolytic Proteins
Plasma antiplasmin and plasminogen were measured by chromogenic as-
says (STA Stachrom 2 antiplasmin and STA Stachrom plasminogen;
DiagnosticaStago). PlasmaPAI-1 antigen levelsweremeasured by anELISA
(AmericanDiagnostica,Greenwich,Conn).Thrombinactivatablefibrinolysis
inhibitor (TAFI) antigen was determined with an ELISA (Chromogenix, Le-
xington, Mass). Plasma TAFI activity was measured by a chromogenic assay
using the Actichrome Plasma TAFI Activity Kit (American Diagnostica).
Soluble thrombomodulin was measured by an ELISA (Diagnostica Stago).
Fibrin clot lysis time (CLT) was measured as described.15 Briefly, citrated
plasma was mixed with 15 mmol/L calcium chloride, 10,000-diluted human
tissue factor (Innovin; Dade Behring), 12 mmol/L phospholipid vesicles, and
60 ng/mL recombinant tissue-type plasminogen activator (Boehringer
Ingelheim, Ingelheim, Germany). Turbidity of this mixture was measured at
405 nm at 37C. CLTwas defined as the time from the midpoint of the clear-
to-maximum-turbid transition,which represents clot formation, to themidpoint
of the maximum-turbid-to-clear transition, representing the lysis of a clot.
Platelet and Endothelial Cell Activation
vWF antigen (Diagnostica Stago), and 2 platelet activation markers,
that is, soluble CD40 ligand (sCD40L; R&D Systems, Indianapolis, Ind),
and P-selectin (R&D Systems) also were measured in plasma.
All the hemostatic measurements were performed by technicians
blinded to the sample status. The coefficients of intra-assay and interassay
variations were less than 9%.
Statistical Analysis
Data are expressed as the mean SD for normally distributed variables or
as themedian (interquartile range) for non-normallydistributedvariables. The
Kolmogorov-Smirnov test was used to assess conformity with a normal
distribution.Categoric valueswere analyzedusing thec2 test.Continuousvar-
iableswere comparedby the Student t testwhendistributed normally or by the
Mann-Whitney U test for non-normally distributed variables. Correlations
between the individualparameterswere calculatedusing thePearsonorSpear-
man rank correlation as appropriate. All clinical and laboratory variables that
showed an association with thrombosis in the univariate model (P<.05) and
did not show substantial correlations (r 0.4) with another independent vari-
able were included in the stepwise multiple logistic regression analysis. The
statistical analyses were performed with the Statistica 9.0 software (StatSoft,
Tulsa, Okla).
The study was powered to have a 90% chance of detecting a 10%
difference in vWF using a P value of .001, based on the values of vWF
in the previous article.14 To show a difference of this magnitude or greater,
28 patients were required in each group.RESULTS
The majority of patients had the left ventricular type of
single ventricle and they were in New York Heart Associa-
tion class I or II (Table 1). The Fontan patients had a lower
white blood cell and platelet counts, and a higher red blood
cell count, hemoglobin level, alanine aminotransferase
level, creatinine level, and international normalized ratio
compared with the controls (Table 2).Coagulation Factors and Inhibitors
Compared with the controls, Fontan patients had lower
values (from 19% to 35%) of all coagulation factors anddiovascular Surgery c Volume 147, Number 4 1285
TABLE 1. Patient characteristics
Variable Fontan patients (n ¼ 48)
Age at Fontan surgery (y) 5 (1-17)
Postoperative time (y) 18 (3-30)
Anatomic diagnosis, n (%)
Tricuspid atresia 20 (42)
VSD, pulmonary atresia 9 (18.5)
Hypoplasia of right ventricle 10 (21)
Double-outlet right ventricle with
hypoplastic left ventricle
9 (18.5)
Ventricle type, n (%)
Right ventricle 9 (19)
Left ventricle 39 (81)
Type of Fontan, n (%)
Atriopulmonary connection 16 (33.3)
Total cavopulmonary connection 29 (60.4)
Modified Fontan 3 (6.3)
Fenestration, n (%) 11 (23)
Systemic ventricle function, n (%)
Good 25 (52)
Fair 16 (33)
Decreased 5 (11)
Poor 2 (4)
NYHA functional class, n (%)
I 14 (29)
II 32 (67)
III 2 (4)
IV 0
Cardiac rhythm, n (%)
Sinus rhythm 42 (88)
Atrial fibrillation 4 (8)
Pacemaker 1 (2)
Medication use, n (%)
Warfarin 10 (21)
Aspirin 16 (33)
Prednisone 3 (6)
Mean oxygen SaO2 on room air (%) 92 (90-97)
Data are presented as median (interquartile range) or number (%). VSD, Ventricular
septal defect; NYHA, New York Heart Association; SaO2, oxygen saturation.
TABLE 2. Comparison of Fontan patients and controls
Variable
Controls
(n ¼ 36)
Fontan patients
(n ¼ 48) P value
Age at enrollment (y) 27 (19-40) 25 (18-40) .06
Male, n (%) 19 (57) 26 (54) .23
BMI (kg/m2) 22  3 22  3 .43
WBC (103/mL) 6.1  1.4 5.5  1.6 .023
RBC (109/mL) 4.9 [0.3] 5.2 [0.9] .001
Hematocrit (%) 46  3 46  3 .84
Platelet count (103/mL) 226  36 148  48 <.001
ALT (IU/L) 24  9 29  12 .016
Total protein (g/dL) 73 [5] 74 [11] .36
Creatinine (mmol/L) 69  11 74  15 <.001
CRP (mg/L) 1.6 [1.6] 1.6 [3.7] .99
INR 0.97 [0.2] 1.1 [0.2] .003
Data are presented as mean SD, median [interquartile range], or number (%). BMI,
Body mass index; WBC, white blood cell; RBC, red blood cell; ALT, alanine
aminotransferase; CRP, C-reactive protein; INR, international normalized ratio.
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normal ranges (Table 3). Interestingly, the patients had
higher antithrombin and free TFPI levels, whereas the
protein C level was similar in both groups. SaO2 correlated
positively with prothrombin (r ¼ 0.38; P ¼ .009),
FV (r ¼ 0.49; P ¼ .001), FVIII (r ¼ 0.32; P ¼ .03), and
FX (r ¼ 0.31; P ¼ .03), and free protein S (r ¼ 0.4;
P ¼ .005). Compared with the controls, Fontan patients
showed higher thrombin generation, reflected by increased
prothrombin fragments F1.2. There was a positive correla-
tion between F1.2 and age (r ¼ 0.32; P ¼ .03), but not
with SaO2 or clinical variables (data not shown).Fibrinolysis
The Fontan patients had higher PAI-1 antigen levels than
the controls, however PAI activity was similar in both1286 The Journal of Thoracic and Cardiovascular Surgroups (Table 3). Interestingly, TAFI activity was higher
by 24% (P<.001) in the patients despite comparable levels
of TAFI antigen (Table 3). A global fibrinolysis marker,
CLT, was 16% (P< .001) longer in the Fontan patients
than in the controls.
CLT in the Fontan patients showed positive associations
with PAI-1 antigen (r ¼ 0.71; P< .001), TAFI activity
(r ¼ 0.69; P < .001), and prothrombin fragments F1.2
(r ¼ 0.74; P<.001). TAFI activity correlated with PAI-1
activity (r ¼ 0.6; P< .001), PAI- 1 antigen (r ¼ 0.58;
P<.001), and F1.2 (r ¼ 0.41; P ¼ .004).Platelet and Endothelial Activation Markers
sP-selectin and sCD40L were higher by 92% and 25%,
respectively, in Fontan patients. We also found vWF to be
23% higher in Fontan patients (Table 3). Therewere inverse
correlations between sP-selectin and SaO2 (r ¼ 0.52;
P < .001), prothrombin (r ¼ 0.35; P ¼ .01), FV
(r ¼ 0.4; P ¼ .005), FVIII (r ¼ 0.33; P ¼ .02), FIX
(r ¼ 0.37;, P ¼ .01), FX (r ¼ 0.38; P ¼ .009), and
free protein S (r ¼ 0.48; P ¼ .001).
None of the clinical characteristics in the Fontan
patients showed associations with fibrinolytic, platelet, or
endothelial markers (data not shown).Fontan Patients With Thrombosis
Previous arterial or venous thromboembolism occurred
in 10 (21%) patients 5 to 15 years (median, 12 y) after
the Fontan surgery. Three patients developed thrombi in
the Fontan circulation, 4 patients had previous deep vein
thrombosis, 1 patient had an isolated pulmonary embolism,
and, finally, 2 patients had both previous ischemic stroke
and deep vein thrombosis. Only 1 patient with a prior
thromboembolism had thrombophilia (ie, heterozygous
FV Leiden mutation).gery c April 2014
TABLE 3. Coagulation factors/inhibitors, fibrinolysis variables, and platelet and endothelial activation markers in Fontan patients and controls
Variable Controls (n ¼ 36) Fontan patients (n ¼ 48) P value
Coagulation factors and inhibitors
FII (%) 109  16 87  17 <.001
FV (%) 104  15 73  24 <.001
FVII (%) 102 [14] 82 [18] <.001
FVIII (%) 132  28 108  29 .001
FIX (%) 114  20 75  20 <.001
FX (%) 115  21 87  24 <.001
Fibrinogen (g/L) 3.2  1.3 2.4  0.5 .005
Prothrombin fragments F1.2 (pmol/L) 185 [31] 263 [74] <.001
Antithrombin (%) 99  14 109  13 .001
Free TFPI (ng/mL) 17 [4] 25 [9] <.001
Protein C (%) 105 [18] 103 [23] .42
Free protein S (%) 95 [13] 85 [13] <.001
Fibrinolysis variables
a2AP (%) 102  9 100  12 .29
Plasminogen (%) 102  10 104  12 .67
PAI-1 activity (IU/mL) 9  1.1 9  3 .28
PAI-1 antigen (ng/mL) 14  4 26  6 <.001
TAFI activity (mg/mL) 25  4 31  8 <.001
TAFI antigen (%) 106  14 104  11 .72
CLT (min) 80  12 93  14 <.001
Platelet and endothelial activation markers
vWF (%) 122  20 150  28 <.001
sP-selectin (ng/mL) 142  29 273  69 <.001
sCD40L (pg/mL) 361  76 450  156 .006
TM (ng/mL) 3.9 [2.2] 3.0 [2.9] .1
Data are presented asmean SDormedian [interquartile range].a2AP, Antiplasmin;CLT, clot lysis time; sCD40L, soluble CD40 ligand; TM, thrombomodulin;F, factor; TFPI, free
tissue factor pathway inhibitor;PAI-1, plasminogenactivator inhibitor-1;TAFI, thrombin activatable fibrinolysis inhibitor; vWF, vonWillebrand factor; sP-selectin, solubleP-selectin.
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DThe Fontan patients with a history of thrombosis had
a lower SaO2. Moreover, lower values of FV, FVIII, and
free protein S were observed. Interestingly, increased
vWF, sCD40L, and P-selectin were found in these patients
(Table 4). Other clinical and hemostatic parameters were
not affected by a history of thrombosis. The multivariate
model showed that free protein S and sCD40L were the
only independent predictors of thromboembolic events
late after Fontan surgery (c2 ¼ 30.7, P<.001; Table 5).
DISCUSSION
We present a comprehensive evaluation of blood
coagulation, fibrinolysis, platelet, and endothelial cell
activation in adult patients who underwent the Fontan
procedure in their childhood or adolescence. The major
findings of our study were uniformly decreased coagulation
factors in adult Fontan patients with a paradoxically
increased thrombin generation in the circulating blood,
probably owing to enhanced platelet activation and
endothelial injury coupled with a slightly lower inhibition
of thrombin formation by reduced free protein S.
Our study clearly indicates that there are complex
hemostatic disturbances in adult Fontan patients. On the
one hand, they seem to favor bleeding by reduction of
coagulation factor production, and on the other hand theyThe Journal of Thoracic and Carpromote thrombosis through reduced protein S, hypofibri-
nolysis, impaired endothelial function, and increased
platelet activation. However, the net effect of all the
hemostatic disturbances in Fontan patients tilts the balance
toward prothrombotic tendency.
Of note, we observed different patterns of hemostatic
alterations in adult Fontan patients as compared with those
reported previously in children mostly in the early postopera-
tive period. In adult patients late after the Fontan surgery, we
found significant reductions in coagulation factors including
FVIII (all the individual alterations were mild and did not
exceed the normal ranges). However, bleeding is fairly
uncommon in Fontan patients, which suggests that despite
a lower platelet count and coagulation factors, other potent
mechanisms can overcome these alterations, leading to
a prothrombotic state as evidenced by heightened thrombin
generation and reflected by increased F1.2 levels. Interest-
ingly, therewere significantly increased levels of2 coagulation
inhibitors, liver-derived antithrombin and endothelium-
derived free TFPI, in the Fontan patients as compared with
controls. It might be hypothesized that this phenomenon is
a compensatorymechanismaiming at restoring the hemostatic
balance when larger amounts of thrombin are generated.
Of note, our study shows an impaired fibrinolytic
potential in adult Fontan patients and hypofibrinolysis isdiovascular Surgery c Volume 147, Number 4 1287
TABLE 4. Comparison between Fontan patients without and with thrombosis
Variable Patients without thrombosis (n ¼ 38) Patients with thrombosis (n ¼ 10) P value
Age at enrollment, (y) 24 (18-40) 27 (18-36) .18
Age at surgery, (y) 6.9 (1-16) 5.6 (2-17) .19
Postoperative time, (y) 17 (3-30) 21 (14-27) .09
Male, n (%) 20 (53) 6 (60) .68
Anatomic diagnosis, n (%) .2
Tricuspid atesia 16 (42) 4 (40)
VSD, pulmonary atesia 6 (16) 4 (40)
Hypoplasia of right ventricle 7 (18) 2 (20)
Double-outlet right ventricle with
hypoplasia of left ventricle
9 (24) 0 (0)
Ventricle type, n (%) .07
Right ventricle 9 (24) 0 (0)
Left ventricle 29 (76) 10 (100)
Type of Fontan, n (%) .2
Atriopulmonary connection 16 (42) 0 (0)
Total cavopulmonary connection 19 (50) 10 (100)
Modified Fontan 3 (8) 0 (0)
Systemic ventricle function, n (%) .13
Good 21 (55) 4 (40)
Fair 13 (34) 3 (30)
Decreased 2 (6) 3 (30)
Poor 2 (5) 0 (0)
NYHA functional class, n (%) .49
I 12 (31) 2 (20)
II 25 (66) 7 (70)
III 1 (3) 1 (10)
IV 0 0
SaO2 (%) 92 [6] 84 [8] .003
Platelet count (103/mL) 142 [49] 152 [44] .79
Hematocrit (%) 44  7 49  3 .07
Prothrombin (%) 89  15 79  22 .1
FV (%) 82 [25] 61 [20] .058
FVII (%) 82 [19] 80 [15] .64
FVIII (%) 113 [28] 82 [26] .03
FIX (%) 75 [20] 67 [22] .23
FX (%) 89  25 80  18 .28
Antithrombin (%) 110  12 105  15 .22
Protein C (%) 104  26 102  28 .85
Free protein S (%) 89  10 70  9 <.001
PAI-1 antigen (ng/mL) 26  6 25  6 .67
PAI-1 activity (IU/mL) 9  3 9  3 .65
TAFI antigen (%) 104  11 104  12 .93
TAFI activity (ug/mL) 31  8 32  9 .69
CLT (min) 91 [15] 89 [12] .34
Prothrombin fragments F1.2 (pmol/L) 261 [76] 275 [73] .88
Plasminogen (%) 104  11 100  15 .3
a2AP (%) 99  12 103  11 .45
vWF (%) 144  23 174  33 .002
sP-selectin (ng/mL) 251  55 353  18 <.001
sCD40L (pg/mL) 417  134 579  173 .003
Data are presented as mean SD, median [interquartile range], or number (%). VSD, Ventricular septal defect; NYHA, New York Heart Association; TAFI, thrombin activatable
fibrinolysis inhibitor; a2AP, antiplasmin; sCD40L, soluble CD40 ligand; SaO2, oxygen saturation; F, factor; PAI-1, plasminogen activator inhibitor-1; CLT, clot lysis time;
vWF, von Willebrand factor; sP-selectin, soluble P-selectin.
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Ddriven mostly by increased TAFI activity. Increasing
evidence indicates that increased TAFI levels occur in
venous thromboembolism and ischemic stroke.16,171288 The Journal of Thoracic and Cardiovascular SurHigh TAFI activity in Fontan patients is a novel finding
and it might contribute to late thromboembolism in this
population. To assess fibrinolysis efficiency, we used thegery c April 2014
TABLE 5. Univariate and multivariate predictors for thrombosis in Fontan patients
Variable
Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
SaO2 (%) 0.87 (0.78-0.97) .015
Free protein S (%) 0.81 (0.71-0.93) .003 0.77 (0.63-0.94) .012
P-selectin (ng/mL) 15.0 (2.6-85.2) .003
vWF (%) 1.04 (1.01-1.07) .014
sCD40L (pg/mL) 1.89 (1.16-3.09) .012 2.71 (1.08-6.82) .034
Factor VIII (%) 0.97 (0.94-0.99) .049
CI, Confidence interval; sCD40L, soluble CD40 ligand; vWF, von Willebrand factor; SaO2, oxygen saturation.
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initiated by a tissue factor without addition of human
thrombin, and tissue-type plasminogen activator is used.18
In our study, CLT was prolonged in adult Fontan patients
and correlated positively with PAI-1 antigen, TAFI activity,
and F1.2. It remains to be established whether CLT might
help identify subjects at increased risk of thromboembolic
events among those patients.
In adult Fontan patients, nonpulsative flow in the pulmo-
nary circulation, slow venous flow, and hypoxemia may
damage endothelial cells. We observed evidence for
endothelial injury in Fontan patients as reflected by
increased plasma vWF levels. It has been postulated that
vWF is a marker of endothelial dysfunction in contrast to
thrombomodulin, which increases subsequent cell mem-
brane injury.19,20
Unexpectedly, we observed that Fontan patients with
prior thromboembolism had lower FV and FVIII, both of
which are associated with SaO2, and free protein S. Cheung
et al21 reported that systemic oxygen blood saturation
correlated positively with plasma levels of anticoagulant
and procoagulant factors, and those abnormalities preceded
the Fontan procedure with a tendency to normalize after the
surgery in association with improved systemic oxygenation.
A decrease of SaO2 in adults after Fontan surgery may
result from a right-to-left shunt through an atrial fenestra-
tion or venovenous collaterals. Atz et al22 observed lower
rest SaO2 without an increased risk of thrombosis during
an 8-year follow-up period in Fontan patients with fenestra-
tion. In our study therewere no differences in the prevalence
of fenestration between the patients with and without
a history of thrombosis. Desaturation also could reflect
a progressive decrease in single-ventricle competence and
an increase in pulmonary pressure.1,2,7 This mechanism is
likely to cause lower SaO2 in our patients.
A novel finding of the present study was increased
platelet activation, as evidenced by higher sP-selectin and
sCD40L in Fontan patients who experienced thromboem-
bolic events. P-selectin, largely derived from activated
platelets, is considered a marker of inflammation or platelet
activation, but it also can induce procoagulant activity
through increased tissue factor expression.23 Despite
significantly reduced coagulation factor levels, it is likelyThe Journal of Thoracic and Carthat by providing a catalytic surface for prothrombinase
complex formation, in combination with reduced levels of
free protein S, activated platelets largely contribute to
a prothrombotic tendency in Fontan patients. Of note,
none of the patients with previous thromboembolism was
taking aspirin at the time of blood collection, which might
have resulted in increased platelet activation. There is
evidence that low-dose aspirin is not potent enough to
reduce circulating levels of platelet-derived proteins
significantly (eg, sCD40L24).
Several limitations of the study should be acknowledged.
First, the number of patients in the study was small and
the patients were heterogeneous with respect to cardiac
diagnosis and the Fontan surgery type. However, our group
is representative of the current growing adult Fontan patient
population in the real-life clinical practice. Second, the true
incidence of thrombosis may have been underestimated
because we analyzed only symptomatic events. Because
patients were studied post hoc after thromboembolic events,
we cannot exclude that the abnormalities observed in
this subset are to some extent secondary to thrombosis.
However, given a long period of time that elapsed since
the event, it is unlikely that the abnormalities are solely
the result of past thromboembolism. Coagulation factors
and inhibitors were not determined at the time of the index
event, and it is known that transient increases in coagulation
factors, particularly FVIII, and decreases in natural
anticoagulants, especially antithrombin and protein C, are
observed commonly during acute thrombosis. Therefore,
changes during acute thrombosis are perceived as a poor
predictor of overall function of the hemostatic system in
human beings.
In conclusion, we found that adult Fontan patients
are characterized by specific abnormalities in blood
coagulation, enhanced platelet activation, and endothe-
lial injury, associated with heightened thrombin
formation and impaired fibrinolysis. Patients show
reduced free protein S, increased platelet activation,
and endothelial damage after thromboembolic events
observed late after Fontan surgery. Further studies are
needed to evaluate the potential benefits from combined
antiplatelet and anticoagulant thromboprophylaxis in
Fontan patients.diovascular Surgery c Volume 147, Number 4 1289
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